El receptor del factor de crecimiento epitelial EGFR como diana terapéutica en cáncer colorrectal

Novel targeted therapies which can block the epidermal growth factor receptor (EGFR) have demonstrated activity in the laboratory and in clinical settings. Different agents have been developed and are being tested in cancer patients. Studies have shown active single-agent efficacy and efficacy in combination with chemotherapy and/or radiation therapy Some published data have shown that Epidermal Growth Factor (EGF) mediates colorectal cancer growth. These observations suggest antiEGFR-targeted therapies including anti-EGFR monoclonal antibodies, immunotoxin conjugates, and EGFR tyrosine-kinase inhibitors can play a role in the treatment of colorectal cancer. New studies aimed at blocking this signaling pathway are needed to elucidate the role of these promising new targeted therapies in the treatment of colorectal cancer.